LAUSANNE, Switzerland, Nov. 4, 2024
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a
commercial-stage global leader and pioneer in the field of antibody
drug conjugates (ADCs), today announced participation in two
investor conferences in November:
Guggenheim Securities Healthcare Innovation Conference
Date: November 11, 2024
Presentation Time: 11:00 a.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief
Executive Officer
Jefferies London Healthcare Conference
Date: November 19, 2024
Presentation Time: 11:00 a.m. GMT
Format: Fireside Chat
Speaker: Ameet Mallik, Chief
Executive Officer
Live webcasts of the presentations will be available via the
Events & Presentations page in the Investors section of ADC
Therapeutics' website, ir.adctherapeutics.com. A replay of each
webcast will be available for approximately 30 days following each
event.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in
London and New Jersey. For more information, please visit
the Company website at adctherapeutics.com and follow us on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
CONTACTS:
Investors
Marcy
Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-present-at-november-investor-conferences-302294663.html
SOURCE ADC Therapeutics SA
